In its heated severe asthma fight with AstraZeneca’s Fasenra, GlaxoSmithKline could take solace in the fact that its drug was more convenient for patients, with a self-administered injection option.
Nucala (mepolizumab) is a brand-name subcutaneous injection that comes in different forms. Depending on which form you’re prescribed, you or your doctor will administer the injection. Nucala injection ...
Most people with asthma are able to control their symptoms by using inhaled medicines each day. But for some people with severe asthma, inhaled medicines are not enough to keep symptoms under control.
GlaxoSmithKline’s Nucala needs a win in its fight against AstraZeneca’s Fasenra. Now, it can at least tout a first-data advantage in a rare inflammatory disease. In a phase 3 study, the rate of ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I being given NUCALA? NUCALA contains the active ingredient ...
Third US indication for Nucala demonstrates GSK’s commitment to finding new ways to help patients with eosinophil-driven diseases Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said: ...
May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following the ...
GlaxoSmithKline plc GSK announced positive data from a pivotal phase III study evaluating its asthma drug Nucala (mepolizumab) for another indication called Hypereosinophilic Syndrome (HES), a rare ...
LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and pediatric ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback